Publications by authors named "Keon Uk Park"
Purpose: This 6-year post-marketing surveillance (PMS) study was conducted in South Korea to evaluate the real-world safety and effectiveness of eribulin in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Materials And Methods: During the study period (17 August 2012 to 16 August 2018), case-report files (CRFs) of patients receiving eribulin were collected. The main study endpoint was to assess the safety of eribulin.
Purpose: The TRIUMPH trial was a biomarker-driven umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This analysis focuses on the PIK3CAɑ inhibitor alpelisib (arm 1) in patients with phosphoinositide 3-kinase (PI3K) pathway alterations.
Materials And Methods: Patients with PI3K pathway altered tumors were enrolled in the alpelisib arm of the TRIUMPH study.
Background: This study analyzed the clinical features of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), who developed progressive disease (PD) after immune checkpoint inhibitor (ICI) therapy.
Methods: We retrospectively analyzed 256 patients with R/M HNSCC treated with ICIs at 11 medical centers. Associations between the treatment outcomes-best response, overall survival, and progression-free survival-and various clinical factors were analyzed.
Article Synopsis
- - The study investigates the effectiveness of durvalumab maintenance therapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC) after receiving concurrent chemoradiotherapy (CCRT), comparing those with specific genetic mutations to those without.
- - A total of 339 patients were analyzed, revealing similar progression-free survival (PFS) rates of 21.4 months for wild-type and 21.0 months for mutant groups, while significant differences in PFS were noted based on programmed death-ligand 1 (PD-L1) expression levels.
- - The findings suggest that while genetic mutations did not significantly alter outcomes, PD-L1 expression levels had a notable impact on PFS, highlighting the importance
Article Synopsis
- Breast cancer (BC) exhibits complex genomic changes, but the impact of age and ethnicity on its molecular variations is still not well understood.
- This study analyzed 843 BC patients in the K-MASTER program, focusing on differences between age groups and comparing findings with larger genomic databases to uncover ethnic disparities.
- Key results included a higher frequency of specific mutations in older patients and significant differences in cancer subtypes across ethnic groups, leading to the development of a model to predict responses to platinum-based chemotherapy based on unique molecular signatures.
Article Synopsis
- Identifying genes related to stemness is key for treating metastatic carcinoma effectively.
- The study found that silencing ribosomal protein L9 (RPL9) reduces growth and invasive capabilities in colorectal cancer (CRC) cells by disrupting ID-1 signaling, which is important for cancer cell survival.
- Targeting RPL9 also diminishes the stem cell-like properties in CRC stem cells, implying it could be a promising therapeutic target to improve treatment outcomes and prevent cancer recurrence.
Article Synopsis
- CT-P6, a biosimilar for trastuzumab, is approved for treating HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
- A 1-year post-marketing surveillance study in South Korea evaluated its safety and effectiveness, involving 642 patients treated with CT-P6.
- Results showed that while over half of the patients experienced adverse events, the majority did not indicate new safety concerns, and notable responses were observed in a significant portion of trastuzumab-naïve patients.
Article Synopsis
- This study explored how genetic changes in PI3KCA and cell cycle pathways affect the effectiveness of durvalumab in patients with head and neck squamous cell carcinoma who did not respond to prior platinum-based treatments.
- Data was collected from a phase II trial involving 87 patients segmented into three groups based on their genetic alterations: PIK3CA changes (Group A), cell cycle alterations (Group B), and no significant genetic changes (Group C).
- The results showed no significant differences in treatment outcomes between the groups, but lower neutrophil-lymphocyte and platelet-lymphocyte ratios were associated with better progression-free survival, suggesting these could be useful biomarkers for predicting treatment response.
Article Synopsis
- - This study investigated a targeted treatment approach for patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) through a genomic profile-based trial involving multiple treatment arms.
- - Patients were assigned to different treatment groups based on their genetic profiles, with various inhibitors used, and crossover to an anti-PD-L1 treatment was allowed if their initial therapy failed.
- - The trial enrolled 203 patients and found varying levels of disease control and response rates across different arms, while the treatments were generally well-tolerated with no treatment-related deaths reported.
Article Synopsis
- The study analyzed the effectiveness and safety of lazertinib compared to gefitinib in treating Korean patients with EGFR-mutated non-small cell lung cancer (NSCLC) as part of the phase 3 LASER301 trial.
- A total of 172 patients were randomized to receive either lazertinib (240 mg/day) or gefitinib (250 mg/day), with the main goal of assessing progression-free survival (PFS).
- Results showed that lazertinib significantly improved median PFS (20.8 months) compared to gefitinib (9.6 months) and had a similar safety profile, suggesting lazertinib could be a promising new treatment option for these patients.
We explored accumulated genomic alterations in patients with heavily treated HER2 + metastatic breast cancer enrolled in the KCSG BR18-14/KM10B trial. Targeted sequencing was performed with circulating tumor DNAs (ctDNAs) collected before the treatment of 92 patients. ctDNAs collected at the time of disease progression from seven patients who had a durable response for > 12 months were also analyzed.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on using DNA damage repair (DDR) gene mutations as potential biomarkers to predict the effectiveness of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).
- Researchers analyzed data from 55 NSCLC patients, finding that those with two or more DDR mutations (termed DDR2 positive) had significantly better outcomes compared to those without these mutations, particularly in patients with low PD-L1 expression.
- The results suggest that combining assessments of DDR mutations and PD-L1 expression can enhance the prediction of patient responses to ICIs, leading to more personalized and effective treatment strategies.
We aimed to compare treatment modalities and outcomes by gender in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). We characterized the sex-specific differences and compared the overall survival (OS) between male and female patients in a multicenter cohort of LA-HNSCC. To minimize the observed confounding, propensity score matching was utilized.
View Article and Find Full Text PDFArticle Synopsis
- This study explored the effects of adding bevacizumab to erlotinib for treating patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
- It involved 127 patients, where those who took erlotinib with bevacizumab experienced fewer instances of needing radiotherapy for brain metastasis, though overall progression-free survival (PFS) didn't show significant improvement.
- A subgroup of patients with brain metastasis did show longer PFS with erlotinib plus bevacizumab, but the study noted higher adverse events in this combination treatment group.
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
J Thorac Oncol
February 2023
Article Synopsis
- - Thymic epithelial tumors (TETs) are rare tumors located in the anterior mediastinum, typically treated with platinum-based chemotherapy, but there's no standard treatment after it fails; researchers tested the effects of palbociclib in a phase 2 trial for patients who had already undergone chemotherapy.
- - The trial involved 48 patients with advanced TETs, assessing the medication's efficacy and safety; patients took palbociclib daily for 21 days with a week off, focusing on progression-free survival as the main measure.
- - Results showed a 12.5% objective response rate, with the median progression-free survival lasting 11 months and an overall survival median of 26.4 months
Introduction: Current standard chemotherapy for biliary tract cancer (BTC) has limited survival benefits, and the need for targeted therapies is increasing. This study investigated the genetic profiles and clinical implications of BRCA mutations in patients with advanced BTC.
Methods: Targeted high-throughput sequencing was performed on samples obtained from 25 patients with advanced BTC who had received palliative first-line platinum-based chemotherapy.
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).
Breast
October 2022
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
View Article and Find Full Text PDFTotality outcome of afatinib sequential treatment in patients with mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
Transl Lung Cancer Res
July 2022
Article Synopsis
- Patients with mutation-positive non-small cell lung cancer treated with first-line afatinib inevitably develop resistance, making access to effective second-line treatments crucial for managing disease progression.
- In a study of 737 patients, those who received subsequent osimertinib after acquiring the T790M mutation showed a longer total time on treatment (35.10 months) compared to those who didn't have the mutation and received chemotherapy (18.80 months) or had unknown mutation status (12.00 months).
- The results indicated a high overall response rate (75.7%) for afatinib and notable CNS efficacy, with 67.0% response rate in patients with initial brain metastasis, suggesting that sequential treatment could
Purpose: Although programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors are promising agents for recurrent or metastatic nasopharyngeal carcinoma (NPC), PD-1/PD-L1 inhibitor monotherapy has shown modest efficacy. This study evaluated the efficacy and safety of nivolumab plus gemcitabine in patients with NPC who failed prior platinum-based chemotherapy.
Patients And Methods: This is a phase II, multicenter, open-label, single-arm study.
Article Synopsis
- Ribosomal protein L17 (RPL17) is found to be up-regulated in colorectal cancer (CRC), signaling a potential role in cancer progression that has not been previously studied.
- The research utilized RPL17-specific siRNAs to silence its expression in CRC cells, leading to decreased cell growth, reduced colony formation, and suppressed tumor formation in mouse models.
- Molecular analyses revealed that RPL17 silencing down-regulated key proteins associated with cell proliferation and stemness, suggesting it plays an oncogenic role in CRC by enhancing tumor cell survival and invasive capabilities.
Background: Elderly patients with extensive-disease small-cell lung cancer (ED-SCLC) have a high risk of chemotherapy toxicity due to multiple comorbidities and poor performance status. Although dose modification is often used to avoid toxicity in elderly patients with ED-SCLC, there is little data on the effect of initial dose-reduced chemotherapy on survival outcomes.
Methods And Patients: We retrospectively reviewed 100 elderly patients (≥70 years) with ED-SCLC who received first-line etoposide plus platinum chemotherapy between January 2006 and December 2020.
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Korean J Intern Med
January 2022
Article Synopsis
- - Older patients (aged ≥ 70) with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) represent 18.7% of a cohort studied, showing more advanced disease and worse performance status compared to younger patients.
- - Treatment for these older patients included concurrent chemoradiotherapy (44.5%), surgery (41.0%), and a significant portion (14.5%) who did not complete planned treatment.
- - Results indicated that older patients had a 60% higher risk of death compared to younger counterparts, with those having oral cavity cancer facing the worst survival rates, highlighting the need for tailored research on this age group.
Article Synopsis
- Pharmacological and non-pharmacological treatments for chemotherapy-induced peripheral neuropathy (CIPN) lack comprehensive investigation, prompting a hypothesis that cyclic thermal therapy might enhance blood flow and alleviate symptoms.
- The study involved treatment of patients over 10 days, assessing blood volume through RBC scintigraphy and quality of life using specific questionnaires focused on CIPN.
- Results indicated that cyclic thermal therapy significantly reduced symptom scores and blood volume variance, suggesting it effectively improves blood circulation and alleviates CIPN symptoms.
Article Synopsis
- The study investigates how chemotherapy before surgery (induction chemotherapy, IC) affects outcomes in patients with locally advanced head and neck cancer, focusing on who responds to treatment and their survival rates.
- Out of 445 patients, 158 received IC; those who responded to IC had significantly better survival rates, while non-responders had a much higher risk of mortality.
- Ultimately, the results suggest that a multi-faceted treatment approach is essential for non-responders, while responders benefited similarly from either surgery or concurrent chemoradiotherapy (CCRT).
Article Synopsis
- Big data analysis identified CDCA8 as increasingly active in human hepatocellular carcinoma (HCC), correlating with poorer survival outcomes, but its specific role in HCC development is still unclear.
- Experimental results showed that reducing CDCA8 levels slows down HCC cell growth, colony formation, and migration by causing cell cycle arrest at the G2/M phase, while increasing CDCA8 levels does the opposite.
- CDCA8 influences several genes and proteins, including increasing tumor-suppressive proteins and inhibiting oncogenic pathways in CD133 cancer stem cells, suggesting that targeting CDCA8 could be a promising strategy for HCC treatment and recurrence prevention.